10 月 29 日 ， 马克斯·普朗克物质结构与动力学研究所 Guo Chunyu 作为第一作者兼共同通讯作 者，在 Nature 期刊发表了题为： Many-body interference in kagome crystals （ kagome 晶体中的多体干涉现象 ） 的研究论文 【2】 。 | | | 10 月 29 日，中国农业科学院深圳农业基因组研究所 | （岭南现代农业科学与技术广东省实验室深圳分中心） | | | | | --- | --- | --- | --- | --- | --- | --- | | 黄三文 | | 院士、南京农业大学植物保护学院/农林生物安全全国重点实验室 | 董莎萌 | | | 教授作为共同通讯作者 | | （ | 王路遥 | 、 李宏博 、 | 柯宇航 为 共同第一作者 | | | ） | | ，在 | | Nature 期刊发表了题为： | Plug-in Strategy for Resistance Engineering Inspired by Potato | | | | | NLRome | | （ 受马铃薯 NLR 基因组启发的抗性工程插件策略 | ...

Core Insights - The article discusses the emergence of flexible robotics, which aims to utilize soft materials and flexible actuators to replicate human-like tactile sensations, potentially transforming prosthetics, minimally invasive surgical robots, and wearable devices [2] Group 1: Research Development - A study published in Nature introduces ultrasound-driven artificial muscles made from flexible materials filled with microbubbles that bend when exposed to ultrasound, enabling wireless control for various movements [3] - The design utilizes over 10,000 microbubbles, each precisely sized to resonate at different frequencies, allowing for selective oscillation and distributed thrust, resulting in programmable deformation with high compactness (approximately 3000 microbubbles/mm²), lightweight (0.047 mg/mm²), high strength (about 7.6 µN/mm²), and rapid response (grasping in less than 100 milliseconds) [6][7] Group 2: Applications and Implications - The artificial muscles exhibit excellent scalability from micrometer to centimeter scales, flexibility, and multiple degrees of freedom, with potential applications in flexible robotics, wearable technology, haptic technology, and biomedical instruments [9]

Core Insights - The article discusses the unique longevity and cancer resistance of the bowhead whale, which can live over 200 years, and highlights the role of a specific protein, Cold-inducible RNA-binding Protein (CIRBP), in DNA repair and genomic stability [3][6][11]. Group 1: Bowhead Whale Longevity - The bowhead whale has a lifespan exceeding 200 years, which is significantly longer than that of other mammals, such as mice, which live only 2-3 years [2]. - Despite its large size (over 80 tons) and the expectation of high cancer rates due to DNA mutations, the bowhead whale exhibits low cancer incidence, suggesting a unique genetic mechanism for cancer prevention [2][11]. Group 2: Research Findings - A study published in Nature identified CIRBP as a key protein activated in cold environments that aids in repairing DNA double-strand breaks, contributing to the bowhead whale's longevity and low cancer risk [3][6]. - The research demonstrated that expressing CIRBP in human cells enhances DNA repair capabilities, and in fruit flies, it extends lifespan and increases resistance to DNA-damaging radiation [9][11]. Group 3: Implications for Human Health - The findings suggest that enhancing DNA repair mechanisms could provide significant opportunities for extending human lifespan and improving health [4][11]. - The study indicates that bowhead whales maintain genomic integrity not by relying on additional anti-cancer genes but through superior DNA repair processes [11].

Core Insights - Bayer's commitment to innovation in China's biopharmaceutical sector is highlighted through the successful hosting of the first "Co-Creation New Drug" competition, recognizing six biotech companies for their groundbreaking innovations in oncology, cardiovascular diseases, kidney diseases, immunology, and new technology platforms [1][4][9]. Group 1: Event Overview - The "Bayer Prescription Drug China Open Innovation Day" was held on October 28, 2025, showcasing Bayer's focus on China's innovation and new drug development capabilities [1]. - The event featured discussions among global and local management, industry experts, research institutions, investment firms, and startups, emphasizing Bayer's commitment to integrating into China's pharmaceutical innovation ecosystem [1][3]. Group 2: Strategic Focus - Bayer is concentrating on key research areas, establishing a differentiated pipeline for long-term growth in oncology, cardiovascular diseases, kidney diseases, neurology, rare diseases, and immunology [3][4]. - The company aims to leverage external collaborations to enhance its drug development process, focusing on unmet medical needs and high-value potential areas [3][4]. Group 3: Winning Companies - Six biotech companies were recognized for their innovative achievements: - **Zhihui Medicine** focuses on overcoming tumor resistance mechanisms [5][13]. - **Gaowei Medicine** utilizes advanced algorithms for drug target identification [5][14]. - **Aibelle** is developing next-generation immunotherapies for solid tumors [5][15]. - **Alpha Molecule** targets GPCRs with an AI-driven platform [5][16]. - **Shanghai Yinuo Pharmaceutical** specializes in autoimmune and chronic inflammatory diseases [5][17]. - **Yaoshu Technology** employs organ-on-chip technology for drug discovery [5][18]. - These companies will receive various rewards and support from Bayer, including entry into the Bayer Co.Lab platform and mentorship from experts [5][10]. Group 4: Bayer's Global Strategy - Bayer views China as a core strategic market for global pharmaceutical innovation and is actively exploring diverse external collaborations [4][9]. - The company has established the Bayer Co.Lab platform to support local startups and early-stage innovations, fostering a collaborative ecosystem [10].

Core Viewpoint - The research presents a novel "Plug-in" breeding strategy for potato late blight resistance, addressing a significant global food security threat posed by the pathogen Phytophthora infestans [2][6]. Group 1: Research Findings - The study constructed a potato disease resistance gene resource library, revealing the differentiation characteristics of two types of resistance genes and their co-evolution with pathogens [3]. - The research team identified three new late blight resistance genes through comparative and evolutionary genomics, proposing a new breeding strategy for developing durable resistant potato varieties [3][4]. - A comprehensive "potato NLRome" was created, encompassing 39,211 NLR class resistance genes from 31 wild and 21 cultivated potato genomes, representing a wide diversity of both wild and cultivated potatoes [4]. Group 2: Genetic Insights - The team successfully cloned the Rpi-cph1 and Rpi-cjm1 genes, with the former previously only found in American black nightshade, and demonstrated the widespread presence of atypical NLR integrated domains in the NLRome [4]. - The identification of the Rpi-brk1 gene, which recognizes pathogen effector proteins through its heavy metal-associated (HMA) domain, suggests that the "Plug-in" strategy can broaden the resistance spectrum of potato NLR genes [4]. Group 3: Implications for Agriculture - The findings provide a new solution for tackling potato late blight, a global challenge, and establish a paradigm for discovering resistance genes through comparative and evolutionary genomics [6].

Core Viewpoint - Solid-state lithium metal batteries are considered the next generation of power batteries due to their high energy density and safety, but they face significant challenges in practical working conditions [2]. Group 1: Research Findings - A new study published in Nature introduces the concept of a "ductile solid electrolyte interphase" (SEI), which enhances the mechanical and lithium-ion transport properties of solid-state batteries [3]. - The research team developed a novel plastic SEI that significantly improves cycling stability under high current density and low-temperature conditions [6]. - The plastic SEI maintains structural integrity while enabling rapid ion transport, achieving over 4500 hours of long cycle life at high current density (15 mA/cm²) and high capacity (15 mAh/cm²) [6]. Group 2: Implications and Innovations - This research shifts the traditional focus on "hard" SEI designs to a new emphasis on "ductility," providing a precise construction path from solid electrolyte components to ideal interfaces [7]. - The findings offer a new strategy to address interface failure issues in solid-state batteries and provide important theoretical support for the design of new interface layers, which is crucial for the practical development of solid-state batteries [7].

编辑丨王多鱼 排版丨水成文 卒中 （俗称 中风 ） 是全球死亡和致残的主要原因之一，其中缺血性卒中占比高达 87% 。在缺血性卒中治疗中， 干细胞疗法 因其在卒中后促进神经恢复的潜力 以及治疗时间窗口限制少等优点备受关注。 近日，同济大学生命科学与技术学院 高绍荣 院士团队 王冕 研究员与上海交通大学 李婉露 教授团队合作，在 Nature Communications 期刊发表了题为 ： Injectable Micropore-forming Microgel Scaffold for Neural Progenitor Cells Transplantation and Vascularization after Stroke 的研究论文。 该研究开发了一种 相分离微孔微凝胶 （ PSMM ） - 基质复合支架 ，可用于高效递送 神经祖细胞 （ NPC ） ，能够通过促进血管生成和细胞存活，显著改善卒 中大鼠的神经功能恢复。 研究团队首先使用双水相体系 （海藻酸钠 / 聚乙烯醇） 结合气体剪切微流控的方式，高通量制备了大小可控且具有微米级孔隙的微凝胶。实验结果显示，相较于 纳米级孔隙微凝胶，微米级孔隙 ...

Core Viewpoint - The article discusses the development of a comprehensive biological clock model, LifeClock, which can accurately predict biological age across the entire lifespan, from infancy to old age, based on routine clinical data [6][19]. Group 1: Biological Age vs. Chronological Age - Biological age (BA) is a more accurate measure of an individual's aging process compared to chronological age (CA), as it reflects the accumulated biological damage relative to average individuals of the same actual age [9][12]. - The study highlights the existence of two distinct biological clock models: a "developmental clock" before age 18, which governs growth, and an "aging clock" after age 18, which governs functional decline [7][18]. Group 2: Research Findings and Methodology - The research utilized nearly 25 million clinical visit records to develop LifeClock, which predicts biological age and assesses its association with disease risk and survival outcomes [5][16]. - The AI model EHRFormer was trained using data from 9,680,764 individuals, allowing for high-precision analysis of developmental and aging dynamics [16][21]. Group 3: Implications for Precision Medicine - The findings suggest that the LifeClock model can predict disease risk more accurately than using chronological age alone, potentially transforming the understanding of aging and its relationship with diseases [21]. - This technology is practical and accessible, as it relies on routine clinical data rather than expensive specialized tests, making it easier to implement in existing healthcare systems [23].

信号转导 ，即细胞感知并响应其环境的过程，这对于生命至关重要。在这个过程中， 钙离子 （ Ca² ⁺ ） 是关键角色之一，它们驱动可兴奋细胞的电活动，并调节诸 如肌肉收缩、心跳和神经递质释放等多样化的信号事件。 细胞表面的被称为 钙离子通道 （ C alcium Channels ） 的特殊蛋白质，使细胞能够控制 Ca² ⁺ 的流入，即使其周围存在较高浓度的钠离子 （ Na ⁺ ） 亦是如此。传统的离子通道研究，主要依赖于对天然离子通道蛋白的突变、结构比对或片段拼接，从而推测其结构与功能的关系，然而，这些 方法 难以真正重现离子通道的 离子选择性。 在 人工智能 （AI） 技术的帮助下，我们能否从头设计出一个具有类似离子选择性通过能力的全新离子 通道蛋白？ 2025 年 10 月 22 日，诺贝尔奖得主、华盛顿大学 David Baker 教授团队 （ 刘禹来 博士为第一作者） 在 Nature 期刊发表了题为 ： Bottom-up design of Ca² ⁺ channels from defined selectivity filter geometry 的研究论文。 该研究首次使用 人工智能 （A ...

Core Viewpoint - The article discusses the clinical trial results of TQB3617, a BET inhibitor developed by Zhengda Tianqing, showing acceptable safety and good efficacy in patients with relapsed or refractory lymphoma [2][8]. Summary by Sections Clinical Trial Overview - The phase 1 clinical trial evaluated the safety, pharmacokinetics, and efficacy of TQB3617 in patients with relapsed or refractory lymphoma, with primary endpoints including safety, dose-limiting toxicity (DLT), and recommended phase 2 dose (RP2D) [3]. - A total of 39 patients were enrolled, receiving oral TQB3617 at doses ranging from 0.05 to 0.25 mg daily [3]. Safety and Adverse Events - The most common treatment-related adverse event was thrombocytopenia, occurring in 36% of patients (14 out of 39) [3][5]. - The safety monitoring committee recommended a dose of 0.1 mg daily for phase 2 trials after observing adverse events at higher doses [3]. Efficacy Results - The objective response rate (ORR) was 31% (12 out of 39), with 4 patients achieving complete remission [4][5]. - The ORR for Hodgkin lymphoma patients was 31% (5 out of 16), T-cell lymphoma patients also had an ORR of 31% (5 out of 16), and B-cell lymphoma patients had an ORR of 29% (2 out of 7) [4]. Key Highlights - TQB3617's recommended phase 2 dose was confirmed, demonstrating acceptable safety with thrombocytopenia as the main toxic effect [5]. - The drug exhibited good anti-tumor efficacy with an overall response rate of 31% [5].